Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-39931
Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.
Titel: | Clinical Data on Immunotherapy in Breast Cancer |
VerfasserIn: | Radosa, Julia Caroline Stotz, Lisa Müller, Carolin ![]() Kaya, Askin Canguel ![]() Solomayer, Erich-Franz Radosa, Marc Philipp |
Sprache: | Englisch |
In: | |
Titel: | Breast Care |
Bandnummer: | 15 |
Heft: | 5 |
Seiten: | 450-469 |
Verlag/Plattform: | Karger |
Erscheinungsjahr: | 2020 |
Freie Schlagwörter: | Breast cancer Immunotherapy Immune checkpoint inhibition CAR T-cell therapy Tumor vaccination |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Background: Breast cancer has traditionally been considered to have a low immunogenic potential compared to other tumor entities. Summary: The most extensively studied immunotherapeutic agents for breast cancer to date are immune checkpoint inhibitors, with the results of the IMpassion130 trial leading to the approval of atezolizumab plus nab-paclitaxel for first-line treatment of programmed cell death ligand 1-positive, metastatic, triple-negative breast cancer, and studies in earlier stages have yielded promising results. Other immunotherapeutic options being assessed in phases 2 and 3 trials include vaccine-based therapies and treatment with anti-human epidermal growth factor receptor 2 (H-directed immune-linked antibodies) and substances evaluated in early clinical trials as cellular therapies (adoptive cell therapy and chimeric antigen receptor T cells). Key Messages: Immunotherapy is an emerging modality for the treatment of breast cancer, as evidenced by the plethora of preclinical and clinical concepts and ongoing trials. Early studies established the role of immunotherapeutic agents in the metastatic setting. Ongoing studies will expand our knowledge about the timing of administration, best partners for combination therapy, and predictive biomarkers to guide immunotherapy for breast cancer. |
DOI der Erstveröffentlichung: | 10.1159/000511788 |
URL der Erstveröffentlichung: | https://doi.org/10.1159/000511788 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-399310 hdl:20.500.11880/35937 http://dx.doi.org/10.22028/D291-39931 |
ISSN: | 1661-3805 1661-3791 |
Datum des Eintrags: | 9-Jun-2023 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Frauenheilkunde |
Professur: | M - Prof. Dr. E.-F. Solomayer |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.